TCPI Announces Additional Distribution of Its HealthCheck and Private Label Home Diagnostic Testing and Screening Products.

Business Editors

POMPANO BEACH, Fla.--(BUSINESS WIRE)--Jan. 22, 2001

TCPI, Inc. (OTCBB:TCPI), a developer, manufacturer and marketer of diagnostic products and drug delivery technologies, today announced the addition of four new customers for TCPI's HealthCheck(R) and private label home diagnostic testing and screening products. Combined sales over the next 12 months related to these programs are estimated to be approximately $700,000.

Pathmark Supermarkets will begin carrying the Company's HealthCheck One Step One Minute(TM) Pregnancy Test (single and double test packs) and home screening test for Kidney and Bladder Disease across its chain of 135 stores located throughout the Northeast. Bergen Brunswig Drug Company (NYSE: BBC) will begin marketing private label versions of TCPI's home screening tests for Diabetes, Urinary Tract Infection, and Kidney and Bladder Disease. Brooks Pharmacies will be adding the HealthCheck One Step One Minute Pregnancy Test to its chain of 375 stores located throughout the New England states. And Discount Drug Mart will begin carrying private label versions of the Company's One Step One Minute Pregnancy Test (single and double test packs) throughout its Midwest chain of 46 stores.

"We are pleased to announce the expanded distribution of our branded and private-label home diagnostic products directly to more than 500 retail outlets as well as throughout Bergen Brunswig's extensive system. The addition of these new programs underscores our continued focus on business fundamentals that includes increasing revenue through sales of existing and new products," said Robert M. Morrow, Vice President of Sales and Marketing for TCPI, Inc.

About TCPI

TCPI, Inc. manufactures point-of-care medical diagnostic products for use at home, in physician offices, and other healthcare locations and markets them worldwide through multiple distribution channels under its own HealthCheck(R) brand as well as OEM (original equipment manufacture) and private label programs.

TCPI's key diagnostic products on the market and in development include its HealthCheck(R) brand of at home testing and screening products, noninvasive TD Glucose(TM) Monitoring System for diabetics to monitor glucose levels, HealthCheck Total and HDL Cholesterol Home Screening Tests, professional use TriMeter(TM) system for analytical monitoring of Total and HDL Cholesterol and blood glucose from a finger-stick, drug of abuse screening tests available in TCPI's branded ScanGuard(TM) and private label One-Step slide, strip or multi-test cassette formats, and over-the counter and professional pregnancy and fertility family planning products in multiple formats - including TCPI's accurate and easy to use One Step-One Minute Pregnancy Test(TM).

The Company also owns a patent-protected, proprietary portfolio of transdermal and dermal drug delivery technologies and skin permeation enhancers. TCPI presently holds 26 U.S. and foreign patents, and has 61 domestic and foreign patent applications pending.

Copies of this and other news releases may be obtained free of charge from TCPI's Web site at www.techchem.com.

Forward Looking Statements

Information in this press release, including any information incorporated by reference herein, includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, and is subject to the safe-harbor created by such sections. The Company's actual results may differ significantly from the results discussed in such forward-looking statements.

Statements regarding development and FDA clearance of future products, future prospects, business plans and strategies, future revenues and revenue sources, the resolution of pending litigation, future liquidity and capital resources, healthcare market directions, future acceptance of the Company's products, possible recommendations of healthcare professionals or governmental agencies regarding use of diagnostic products, possible growth in markets for at-home diagnostic testing, the possibility and timing of additional equity investments, mergers, acquisitions or other strategic transactions, as well as other statements contained in this report that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future, and similar statements are forward-looking statements. These statements are based upon assumptions and analyses made by the Company in light of current conditions, future developments and other factors the Company believes are appropriate in the circumstances, or information obtained from third parties and are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that forward-looking statements are not guarantees of future performance and that actual results might differ materially from those suggested or projected in the forward-looking statements. Factors that may cause actual future events to differ significantly from those predicted or assumed include, but are not limited to: the satisfactory conduct and completion of clinical trials demonstrating efficacy of the Company's Products including TD Glucose(TM) Monitoring System and Total Cholesterol Home Screening Test; FDA and foreign regulatory clearance of the TD Glucose Monitoring System and Total Cholesterol Home Screening Test; delays in product development; risks associated with the Company's ability to successfully develop and market new products on a profitable basis or at all; the Company's ability to finance and complete the acquisition of certain assets of Roche Diagnostics GmbH, availability of labor and sufficient parts and materials to complete the design, construction and manufacturing scale-up of required equipment; ability to complete the design, construction and manufacturing scale-up on a timely basis within budget parameters; receipt of any required regulatory approvals for manufacturing equipment or related facilities; future advances in technologies and medicine; the uncertainties of healthcare reform; risks related to the early stage of the Company's existence and its products' development; the Company's ability to execute its business plans, including receipt and shipment of anticipated product orders; engineering development; lead time for delivery of equipment; the Company's dependence on outside parties such as its key customers, suppliers, licensing and alliance partners; competition from major pharmaceutical, medical and diagnostic companies; risks and expense of government regulation and effects of changes in regulation (including risks associated with obtaining requisite FDA and other governmental approvals for the Company's products); the limited experience of the Company in manufacturing and marketing products; uncertainties connected with product liability exposure and insurance; risks associated with domestic and international growth and expansion; risks associated with international operations (including risk associated with international economies, currencies and business conditions); risks associated with obtaining and maintaining patents and other protections of intellectual property; risks associated with uncertainty of litigation and appeals, and the payment of judgments not reversed on appeal or otherwise; the Company's limited cash reserves and sources of liquidity, including the satisfaction of terms and conditions relating to funding, and timing and receipt of proceeds from any funding; uncertainties regarding timing and effectiveness of registration statements; uncertainties in availability of expansion capital in the future and other risks associated with capital markets, including funding of ongoing operations, risks associated with the Company's ability to negotiate and obtain additional financing, equity investments or strategic transactions on favorable terms or at all and the influence, if any, a delay in developing the Company's products, including the TD Glucose Monitoring System and Total Cholesterol Home Screening Test may have on such funding of operations and for obtaining additional financing, equity investments or strategic transactions, as well as those listed in the Company's other press releases and in its other filings with the Securities and Exchange Commission. The Company may determine to discontinue or delay the development of any or all of its products under development at any time. Moreover, the Company may not be able to successfully develop and market new products, complete planned acquisitions, enter into strategic alliances or implement any or all of its operating strategy unless it is able to generate additional liquidity and working capital. For a complete description of the Company's business, products and liquidity, see the Company's Annual Report on Form 10-K for the year ended December 31, 1999 and subsequent quarterly reports on Form 10-Q.